Trial Profile
A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2020
Price :
$35
*
At a glance
- Drugs TCN 202 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Theraclone Sciences
- 13 Dec 2013 Initiation date changed from 10 September 2013 to 27 August 2013, as per Brazilian Clinical Trials Registry record
- 11 Dec 2013 As per Brazilian Clinical Trials Registry record, the expected date of last enrollment is 31 May 2014
- 11 Dec 2013 As per the Brazilian Clinical Trials Registry record; the primary endpoint has been changed form viral load to proportion of patients receiving the CMV infection. The dose has been changed from 1 mg/ kg to 15 mg/kg.